Floatz logo

Vcl-Cb01

Chronic Myelogenous Leukemia

Astellas Pharma IncvaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

86 Active assets in the Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

Vcl-Cb01 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
Hodgkins lymphomaDormant
B
Indicative ·
57 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →